AZ HB2489

Amends Arizona Revised Statutes to allow prescribing of FDA-approved MDMA (3,4-methylenedioxymethamphetamine) medications that have been rescheduled by the DEA from Schedule I to another controlled substance schedule.

Adds section 36-2517.01 to Arizona law establishing that MDMA-containing compounds approved by the FDA and rescheduled by the DEA can be legally prescribed in Arizona.

Legislation is conditional and does not take effect unless an MDMA investigational product receives FDA approval as a prescription medication and is controlled under a federal interim final rule by January 1, 2026.

Requires the Arizona State Board of Pharmacy to notify the Arizona Legislative Council by February 1, 2026 of whether the effective date condition was met.

Cites legislative findings that approximately 13 million Americans have post-traumatic stress disorder and identifies MDMA-assisted therapy as a potential treatment option needing rapid patient access.